X4 Pharmaceuticals, Immuneering and Tango Therapeutics Are Getting New Analyst Attention

Analyst sentiment across three small-cap biotechs has turned notably positive, with fresh coverage initiations and maintained Buy-equivalent ratings from institutional research desks ahead of 2026 clinical catalysts.